JP2012510499A - 生体内イメージング法 - Google Patents

生体内イメージング法 Download PDF

Info

Publication number
JP2012510499A
JP2012510499A JP2011538991A JP2011538991A JP2012510499A JP 2012510499 A JP2012510499 A JP 2012510499A JP 2011538991 A JP2011538991 A JP 2011538991A JP 2011538991 A JP2011538991 A JP 2011538991A JP 2012510499 A JP2012510499 A JP 2012510499A
Authority
JP
Japan
Prior art keywords
vivo
vivo imaging
contrast agent
imaging moiety
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011538991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510499A5 (enExample
Inventor
ジョーンズ，ポール・アレキサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2012510499A publication Critical patent/JP2012510499A/ja
Publication of JP2012510499A5 publication Critical patent/JP2012510499A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011538991A 2008-12-02 2009-12-01 生体内イメージング法 Withdrawn JP2012510499A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11906008P 2008-12-02 2008-12-02
GBGB0821994.1A GB0821994D0 (en) 2008-12-02 2008-12-02 In viva imaging method
US61/119,060 2008-12-02
GB0821994.1 2008-12-02
PCT/EP2009/066120 WO2010063701A2 (en) 2008-12-02 2009-12-01 In vivo imaging method

Publications (2)

Publication Number Publication Date
JP2012510499A true JP2012510499A (ja) 2012-05-10
JP2012510499A5 JP2012510499A5 (enExample) 2012-12-27

Family

ID=40262535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011538991A Withdrawn JP2012510499A (ja) 2008-12-02 2009-12-01 生体内イメージング法

Country Status (6)

Country Link
US (1) US20110236307A1 (enExample)
EP (1) EP2389200A2 (enExample)
JP (1) JP2012510499A (enExample)
CN (1) CN102300589A (enExample)
GB (1) GB0821994D0 (enExample)
WO (1) WO2010063701A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519014A (ja) * 2014-06-25 2017-07-13 ヌカナ バイオメド リミテッド ゲムシタビンプロドラッグ

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101297815B1 (ko) 2010-11-18 2013-09-03 충남대학교산학협력단 폴리감마글루탐산과 광학영상다이의 복합체를 함유하는 센티넬 림프노드 감지용 광학영상 프로브
NZ746901A (en) 2016-03-11 2023-06-30 Ac Immune Sa Bicyclic compounds for diagnosis and therapy
FI3562487T3 (fi) 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN116947836A (zh) 2017-04-26 2023-10-27 巴斯利尔药物国际股份公司 制备呋咱并苯并咪唑及其晶型的方法
WO2019222454A1 (en) 2018-05-16 2019-11-21 Emory University Styrylbenzothiazole derivatives and uses in imaging
US20210252175A1 (en) 2018-06-08 2021-08-19 Ac Immune Sa Novel compounds for diagnosis
US20200085979A1 (en) 2018-09-11 2020-03-19 Stanley Satz Precision medicine theranostics and diagnostics a combination thereof
AU2020207051B2 (en) 2019-01-08 2025-07-24 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7759110B2 (ja) 2020-05-07 2025-10-23 エーシー・イミューン・エス・アー 診断のための新規化合物
US20250042905A1 (en) 2021-11-10 2025-02-06 Ac Immune Sa Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
WO2023083998A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis
MX2024005426A (es) 2021-11-10 2024-05-21 Ac Immune Sa Derivados de 4h-imidazo[1,5-b]pirazol para diagnostico.
WO2024126842A1 (en) 2022-12-16 2024-06-20 Ac Immune Sa Novel compounds for diagnosis
CN120344536A (zh) 2022-12-16 2025-07-18 Ac免疫有限公司 用于诊断的新化合物
WO2025037013A1 (en) 2023-08-16 2025-02-20 Ac Immune Sa Diagnostic compounds that bind to alpha-synuclein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6379650B1 (en) * 2001-03-19 2002-04-30 Wesley Scott Ashton Technetium 99m-N2S2-congo red complexes utilizing diamide dithiolate ligand systems for radioimaging
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US8329142B2 (en) * 2003-05-29 2012-12-11 Pettegrew Jay W Compounds, compositions and methods for medical imaging of Parkinson's disease
US7666886B2 (en) * 2005-07-15 2010-02-23 The Regents Of The University Of California Compounds and methods for the diagnosis and treatment of amyloid associated diseases
EP1971584A2 (en) * 2005-12-01 2008-09-24 University of Pittsburgh - Of the Commonwealth System of Higher Education Isotopically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins
CA2662863A1 (en) * 2006-09-06 2008-03-13 The Board Of Regents Of The University Of Texas System Methods and compositions for the detection of protein folding disorders
SI2074145T1 (sl) * 2006-10-02 2017-12-29 Ac Immune S.A. Humanizirano protitelo proti amiloid beta
WO2008121407A1 (en) * 2007-03-30 2008-10-09 The Regents Of The University Of California In vivo imaging of sulfotransferases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519014A (ja) * 2014-06-25 2017-07-13 ヌカナ バイオメド リミテッド ゲムシタビンプロドラッグ
JP2020152725A (ja) * 2014-06-25 2020-09-24 ヌカナ ピーエルシー ゲムシタビンプロドラッグ

Also Published As

Publication number Publication date
WO2010063701A3 (en) 2010-08-05
EP2389200A2 (en) 2011-11-30
WO2010063701A2 (en) 2010-06-10
GB0821994D0 (en) 2009-01-07
CN102300589A (zh) 2011-12-28
US20110236307A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
JP2012510499A (ja) 生体内イメージング法
ES2348870T3 (es) Composiciones y procedimientos para la formacion de imagenes no invasiva de beta-amiloide soluble.
Chen et al. Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain
JP5043438B2 (ja) 阻害剤造影剤
US20120244074A1 (en) Labelled integrin binders
JP2012506439A (ja) イメージング及び放射線治療法
EP2305316A2 (en) Diphosphorylated glycopeptide imaging agent for fibrosis
US11844846B2 (en) Styrylbenzothiazole derivatives and uses in imaging methods
JP2009518372A5 (enExample)
CN101060865B (zh) 诊断淀粉样蛋白沉积相关疾病的前驱形式的方法
JP4943159B2 (ja) 新規示差画像形成法
Nguyen et al. IBETA: A new aβ plaque positron emission tomography imaging agent for Alzheimer’s disease
JP2023541379A (ja) 神経系の疾患及び障害を改善するための組成物及び方法
JP2009518373A (ja) 線維症用の新規造影剤
US20240390529A1 (en) Dual-mode probe for detecting hydrogen sulfide and use thereof
Chaturvedi et al. Mapping neuroreceptors with metal-labeled radiopharmaceuticals
JP2010529173A (ja) 神経活性の測定
WO2014122228A1 (en) Labelled compounds that bind to alpha-v-beta-3 integrin
JP2008509921A (ja) 内皮特異的な生体内伝達のターゲティング剤としての熱ショックタンパク質
US20080279771A1 (en) Novel Imaging Agents for Cancer
Swann Developing Disease-Targeted Photoacoustic Imaging Probes
CN116801875A (zh) 用于改善神经疾病和病症的组合物和方法
Nguyen et al. [124I] BETA, a new beta-amyloid plaque PET imaging agent for Alzheimer's disease
JP2011528014A (ja) 治療のモニタリング

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131107